

# Resource Summary Report

Generated by [RRID](#) on Aug 28, 2026

## MOLT-4

RRID:CVCL\_0013

Type: Cell Line

### Proper Citation

RRID:CVCL\_0013

### Cell Line Information

**URL:** [https://web.expasy.org/cellosaurus/CVCL\\_0013](https://web.expasy.org/cellosaurus/CVCL_0013)

**Proper Citation:** RRID:CVCL\_0013

**Description:** Cell line MOLT-4 is a Cancer cell line with a species of origin Homo sapiens (Human)

**Sex:** Male

**Disease:** Adult T acute lymphoblastic leukemia

**Defining Citation:** [PMID:165156](#), [PMID:1765142](#), [PMID:2041050](#), [PMID:2140233](#), [PMID:2144611](#), [PMID:2846092](#), [PMID:2985879](#), [PMID:3159941](#), [PMID:3335022](#), [PMID:3874327](#), [PMID:4547172](#), [PMID:4567231](#), [PMID:6181032](#), [PMID:6198871](#), [PMID:6200433](#), [PMID:6582512](#), [PMID:6954533](#), [PMID:8127147](#), [PMID:8316623](#), [PMID:8547074](#), [PMID:8558913](#), [PMID:8641406](#), [PMID:8957066](#), [PMID:9331090](#), [PMID:9510473](#), [PMID:9685479](#), [PMID:9787181](#), [PMID:10071127](#), [PMID:10700174](#), [PMID:10739008](#), [PMID:11021758](#), [PMID:11226526](#), [PMID:11416159](#), [PMID:11986953](#), [PMID:12068308](#), [PMID:15472075](#), [PMID:15748285](#), [PMID:15901131](#), [PMID:16408098](#), [PMID:16957166](#), [PMID:17088437](#), [PMID:17117183](#), [PMID:19372543](#), [PMID:20164919](#), [PMID:20215515](#), [PMID:20922763](#), [PMID:22068913](#), [PMID:22347499](#), [PMID:22384151](#), [PMID:22460905](#), [PMID:22628656](#), [PMID:23856246](#), [PMID:23933261](#), [PMID:24279929](#), [PMID:24670534](#), [PMID:24762992](#), [PMID:25877200](#), [PMID:26295583](#), [PMID:27377824](#), [PMID:27397505](#), [PMID:27807467](#), [PMID:28196595](#), [PMID:28569787](#), [PMID:30894373](#), [PMID:31068700](#), [PMID:31160637](#), [PMID:31733513](#), [PMID:32449352](#), [PMID:35354797](#), [PMID:35839778](#), [PMID:38861359](#)

**Comments:** Population: Caucasian., Part of: NCI-60 cancer cell line panel., Part of: NCI Pediatric Preclinical Testing Program (PPTP) cell line panel., Part of: MD Anderson Cell Lines Project., Part of: LL-100 blood cancer cell line panel., Part of: Human Protein Atlas, Cell Atlas panel., Part of: COSMIC cell lines project., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE)., Part of: 12th International Histocompatibility Workshop (12IHW) cell line panel.

**Category:** Cancer cell line

**Organism:** Homo sapiens (Human)

**Name:** MOLT-4

**Synonyms:** Molt-4, MOLT 4, Molt 4, MOLT.4, MOLT4, Molt4, GM02219, GM02219C, GM2219C, GM02219D

**Cross References:** BTO:BTO\_0000873, CLO:CLO\_0007825, CLO:CLO\_0032246, CLO:CLO\_0050992, EFO:EFO\_0001220, MCCL:MCC:0000335, CLDB:cl3524, CLDB:cl3525, CLDB:cl3527, CLDB:cl3528, CLDB:cl3529, CLDB:cl3530, CLDB:cl3531, CLDB:cl3532, CLDB:cl4976, CLDB:cl5233, ArrayExpress:E-MTAB-38, ArrayExpress:E-MTAB-783, ArrayExpress:E-MTAB-3610, ArrayExpress:E-MTAB-7721, ArrayExpress:E-MTAB-7722, ATCC:CRL-1582, BCRC:60060, BCRJ:0176, BioSample:SAMN03470847, BioSample:SAMN03471400, BioSample:SAMN03472410, BioSample:SAMN03473319, BioSample:SAMN10988202, cancercellines:CVCL\_0013, CCRID:1101HUM-PUMC000043, CCRID:3101HUMTCHu224, CCRID:4201HUM-CCTCC000083, CCTCC:GDC0083, Cell\_Model\_Passport:SIDM00145, ChEMBL-Cells:ChEMBL3307557, ChEMBL-Targets:ChEMBL614177, CLS:300115, Coriell:GM02219, Cosmic:716176, Cosmic:721716, Cosmic:801730, Cosmic:850194, Cosmic:850381, Cosmic:875865, Cosmic:897451, Cosmic:905958, Cosmic:913409, Cosmic:919154, Cosmic:922677, Cosmic:932766, Cosmic:933547, Cosmic:974249, Cosmic:991545, Cosmic:999763, Cosmic:1012099, Cosmic:1019314, Cosmic:1044254, Cosmic:1070704, Cosmic:1071877, Cosmic:1082518, Cosmic:1092615, Cosmic:1115596, Cosmic:1118467, Cosmic:1127263, Cosmic:1130237, Cosmic:1151788, Cosmic:1175131, Cosmic:1175857, Cosmic:1176596, Cosmic:1226858, Cosmic:1305339, Cosmic:1312325, Cosmic:1330500, Cosmic:1483362, Cosmic:1509200, Cosmic:1524808, Cosmic:1639636, Cosmic:1664513, Cosmic:1811158, Cosmic:1998457, Cosmic:2039521, Cosmic:2165720, Cosmic:2361368, Cosmic:2560251, Cosmic:2602924, Cosmic-CLP:905958, dbMHC:48976, DepMap:ACH-001127, DSMZ:ACC-362, DSMZCellDive:ACC-362, ECACC:85011413, ECACC:94022544, EGA:EGAS00001000978, GDSC:905958, GEO:GSM2092, GEO:GSM50196, GEO:GSM50912, GEO:GSM236794, GEO:GSM236830, GEO:GSM743460, GEO:GSM750821, GEO:GSM799348, GEO:GSM799411, GEO:GSM887336, GEO:GSM888412, GEO:GSM1178423, GEO:GSM1178424, GEO:GSM1178425, GEO:GSM1181333, GEO:GSM1181349, GEO:GSM1670128, GEO:GSM1696583, GEO:GSM1696584, GEO:GSM1696585, GEO:GSM1696586, GEO:GSM2124644, GEO:GSM4471876, GEO:GSM5137731, GEO:GSM7701445, GEO:GSM7701446, IARC\_TP53:27042, ICLC:HTL99025, IGRhCellID:MOLT4, IHW:IHW09226, IPD-IMGT/HLA:11094, IZSLER:BS TCL 85, JCRB:IFO50362, JCRB:JCRB9031, KCB:KCB 200940YJ, KCLB:21582, LINCS\_LDP:LCL-1019, Lonza:810, NCBI\_Iran:C149, NCI-DTP:MOLT-4, Pharmacodb:MOLT4\_958\_2019, PRIDE:PXD003539, PRIDE:PXD005942, PRIDE:PXD005946, PRIDE:PXD018565, PRIDE:PXD023662, PRIDE:PXD030304, Progenetix:CVCL\_0013, PubChem\_Cell\_line:CVCL\_0013, RCB:RCB0206, SKY/M-FISH/CGH:2741, Ubigen:YC-C127, Wikidata:Q54906365

**ID:** CVCL\_0013

**Record Creation Time:** 20220427T220817+0000

**Record Last Update:** 20260815T234641+0000

---

## Ratings and Alerts

No rating or validation information has been found for MOLT-4.

No alerts have been found for MOLT-4.

---

## Data and Source Information

**Source:** [Cellosaurus](#)

---

## Usage and Citation Metrics

We found 318 mentions in open access literature.

**Listed below are recent publications.** The full list is available at [RRID](#) .

Ianevski A, et al. (2026) Multiomics Profiling of T-cell Leukemia and Lymphoma Enables Targeted Therapeutic Discovery. *Cancer research*, 86(2), 295.

Liu Z, et al. (2026) Activation-gated, T cell-restricted silencing of Dapk1 enhances Bacille Calmette-Guérin-elicited protective CD4+ memory. *iScience*, 29(5), 115593.

Xingming Z, et al. (2026) Dual regulation of CXCR6+CD8+ T cells modulates cytotoxic and exhaustion-associated programs during prostate cancer progression. *Journal for immunotherapy of cancer*, 14(3).

Yagüe-Capilla M, et al. (2026) IMPDH inhibition enhances cytarabine efficacy in SAMHD1-expressing leukaemia cells via guanine nucleotide depletion. *Molecular oncology*.

Lam C, et al. (2026) HIV-1 establishes immediate latency in T cells expressing the viral Nef protein. *FEBS open bio*, 16(6), 1132.

Cheng J, et al. (2026) Efficacy and safety of autologous CD5-KO anti-CD5 CAR-T cells in relapsed/refractory CD5+ hematological malignancies. *Cell reports. Medicine*, 7(2), 102584.

Price HE, et al. (2026) Activity of Direct KRAS(G12C) Inhibitors in Preclinical Models of Pediatric Cancer. *Molecular cancer therapeutics*, 25(5), 727.

He L, et al. (2026) SATB1 regulates TXNIP inhibiting invasion and infiltration in T-cell acute lymphoblastic leukemia. *Cancer gene therapy*, 33(1), 55.

Wang J, et al. (2026) The phosphatase DUSP2 constrains lymphoid remodeling and immunotherapy response in lung squamous carcinoma. *Molecular therapy : the journal of the American Society of Gene Therapy*, 34(7), 4279.

Zhou Y, et al. (2026) Distinct Regulation of the ARF and TAp73 Tumor Suppressor Genes by the Transcription Factor E2F1 Enables Discrimination of Cancer Cells from Normal Growing Cells. *Cells*, 15(1).

Dong G, et al. (2026) Discovery of SKP2-Recruiting PROTACs for Target Protein Degradation. *Advanced science* (Weinheim, Baden-Wurttemberg, Germany), 13(20), e15159.

Matar S, et al. (2025) Development of a Novel Bifunctional Anti-CD47 Fusion Protein with Improved Efficacy and a Favorable Safety Profile. *Molecular cancer therapeutics*, 24(6), 816.

Costa JR, et al. (2025) Transcription factor cooperativity at a GATA3 tandem DNA sequence determines oncogenic enhancer-mediated activation. *Cell reports*, 44(5), 115705.

Toure MA, et al. (2025) Targeted degradation of CDK9 potentially disrupts the MYC-regulated network. *Cell chemical biology*, 32(4), 542.

Ibrahim NK, et al. (2025) SOD2 is a regulator of proteasomal degradation promoting an adaptive cellular starvation response. *Cell reports*, 44(4), 115434.

Yang C, et al. (2025) A nanobody-based tri-specific NK cell engager targeting CD5 triggers antitumor immunity. *Cell reports. Medicine*, 6(10), 102409.

Liu T, et al. (2025) A generalized strategy to kill leukemic cells by targeting the regulatory systems governing mitochondrial membrane potential. *Cell reports*, 44(11), 116496.

Chen YL, et al. (2025) Chronic ISG15 Exposure Accelerates CD8+ T-cell Dysfunction while Increasing PD-1 Blockade Sensitivity in Oral Squamous Cell Carcinoma. *Cancer immunology research*, 13(11), 1829.

Xu J, et al. (2024) Preclinical testing of CT1113, a novel USP28 inhibitor, for the treatment of T-cell acute lymphoblastic leukaemia. *British journal of haematology*, 204(6), 2301.

Calbert ML, et al. (2024) 4'-Ethynyl-2'-Deoxycytidine (EdC) Preferentially Targets Lymphoma and Leukemia Subtypes by Inducing Replicative Stress. *Molecular cancer therapeutics*, 23(5), 683.